ATLAS News · Earnings

Moderna Raises Revenue Outlook After Q3 2026 Earnings Beat

Published November 6, 2026 · 6 sources

Moderna reported third-quarter 2026 results above forecasts and raised its full-year sales growth outlook, outlets report, with Covid vaccine sales a key factor.

What happened

Moderna (NASDAQ:MRNA) reported third-quarter 2026 earnings and revenue that came in above analyst expectations, according to Yahoo Finance, Quartz and StreetInsider. The company also raised its revenue outlook.

Yahoo Finance reports that Moderna lifted its full-year sales growth forecast and increased its projected year-end cash balance. Yahoo Finance and StreetInsider both say shares jumped 10% following the report.

NDTV Profit links the higher guidance to Covid vaccine sales. Barron's notes that the stock is up 700% on enthusiasm for its cancer vaccine, but says the earnings show Covid products still matter. MarketScreener lists the results for the third quarter and the nine months ended September 30, 2026.

Context

Moderna is a biotechnology company best known for its mRNA-based Covid vaccine, and it has also been developing other mRNA products, including cancer vaccines.

Why it matters

The results suggest Covid vaccine revenue remains an important part of Moderna's financial picture alongside investor interest in its cancer vaccine work.

Stocks in this story

Price changes are shown for the trading day of the story and are a coincidence in time, not proof that the news caused them. Figures are ATLAS data from our database.

ModernaMRNA

+7.16%

Healthcare · NASDAQ

Latest price during the session: $258.76+7.16% vs. previous close ($241.47)
Chance of a rise in 1 month: 43%Probability of closing higher than today within 21 sessions.Normal range: half of the scenarios end between $202.41 and $300.13; 9 in 10, between $142.75 and $425.55.

See the full ATLAS analysis of Moderna →

Closing prices, fair value and probabilities: ATLAS own data. How we calculate fair value.

Sources

ATLAS writes its own summaries from the reporting of these outlets. Each link opens the original publisher.

Moderna Stock Is Up 700% on Cancer Vaccine Hype. Earnings Reveal That Covid Still Counts. · Barron's · November 6, 2026
Moderna Shares Jump 10% as Q3 Earnings Beat Forecasts and Revenue Outlook Improves · Yahoo Finance · November 6, 2026
Moderna raised its sales outlook after Q3 2026 profit beat estimates · Quartz · November 6, 2026
Moderna Boosts Revenue Guidance on Covid Vaccine Sales · NDTV Profit · November 6, 2026
Moderna shares surge 10% on earnings beat and raised revenue outlook · StreetInsider · November 6, 2026
Moderna, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026 · marketscreener.com · November 6, 2026

Latest market news · Markets today on ATLAS · Moderna

What you get with ATLAS

Create my ATLAS account →

Fair value, probabilities and earnings for every stock. Free account, no card. Information, not advice.

Information, not advice. This content is informational and is not an investment recommendation or an offer to buy or sell securities. ATLAS estimates come from statistical models using public data, can be wrong, and past performance does not guarantee future results. Disclaimer